Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
February 01 2021 - 7:32PM
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing
next-generation vaccines for serious infectious diseases, today
announced that Gregory M. Glenn, M.D, President of Research &
Development, will present on NVX-CoV2373, the company’s COVID-19
vaccine, at The New York Academy of Science (NYAS) event, ‘The
Quest for a COVID-19 Vaccine.’
Webinar details are as follows:
Presentation title: |
Efficacy Data Updates from Novavax’ Protein-based Vaccine
Candidate |
Date: |
February 2, 2021 |
Time: |
4:00 pm ET |
Presenter: |
Dr. Glenn |
Novavax announced interim data last
week on its protein-based COVID-19 vaccine candidate that
demonstrated efficacy of 89.3% in a pivotal Phase 3 clinical trial
taking place in the United Kingdom (UK). The data from this UK
Phase 3 trial and a South Africa Phase 2b study were the first to
demonstrate clinical efficacy against newer circulating UK and
South Africa COVID-19 variants.
To register for the webinar please visit the
NYAS website. Presentation slides will be posted to the company’s
website following the presentation here.
About NVX-CoV2373
NVX-CoV2373 is a protein-based vaccine candidate
engineered from the genetic sequence of SARS-CoV-2, the virus that
causes COVID-19 disease. NVX-CoV2373 was created using Novavax’
recombinant nanoparticle technology to generate antigen derived
from the coronavirus spike (S) protein and is adjuvanted with
Novavax’ patented saponin-based Matrix-M™ to enhance the immune
response and stimulate high levels of neutralizing antibodies.
NVX-CoV2373 contains purified protein antigen and can neither
replicate, nor can it cause COVID-19. In preclinical studies,
NVX-CoV2373 induced antibodies that block binding of spike protein
to cellular receptors and provided protection from infection and
disease. It was generally well-tolerated and elicited robust
antibody response numerically superior to that seen in human
convalescent sera in Phase 1/2 clinical testing. NVX-CoV2373 is
currently being evaluated in two pivotal Phase 3 trials: a trial in
the U.K that completed enrollment in November and the
PREVENT-19 trial in the U.S. and Mexico that
began in December. It is also being tested in two ongoing Phase 2
studies that began in August: A Phase 2b trial in South
Africa, and a Phase 1/2 continuation in
the U.S. and Australia.
About Matrix-M™
Novavax’ patented saponin-based Matrix-M™
adjuvant has demonstrated a potent and well-tolerated effect by
stimulating the entry of antigen presenting cells into the
injection site and enhancing antigen presentation in local lymph
nodes, boosting immune response.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology
company that promotes improved health globally through the
discovery, development and commercialization of innovative vaccines
to prevent serious infectious diseases. The Company’s proprietary
recombinant technology platform combines the power and speed of
genetic engineering to efficiently produce highly immunogenic
nanoparticles designed to address urgent global health needs.
Novavax is conducting late-stage clinical trials for NVX-CoV2373,
its vaccine candidate against SARS-CoV-2, the virus that causes
COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle
vaccine, met all primary objectives in its pivotal Phase 3 clinical
trial in older adults and will be advanced for regulatory
submission. Both vaccine candidates incorporate Novavax’
proprietary saponin-based Matrix-M™ adjuvant to enhance the immune
response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us
on Twitter and LinkedIn.
Novavax Forward Looking Statements
Statements herein relating to the future
of Novavax and the ongoing development of its vaccine and
adjuvant products are forward-looking
statements. Novavax cautions that these forward-looking
statements are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include those identified under the heading “Risk
Factors” in the Novavax Annual Report on Form 10-K for the year
ended December 31, 2019, and Quarterly Report on
Form 10-Q for the period ended September 30, 2020,
as filed with the Securities and Exchange
Commission (SEC). We caution investors not to place
considerable reliance on forward-looking statements contained in
this press release. You are encouraged to read our filings with
the SEC, available at sec.gov, for a discussion of these
and other risks and uncertainties. The forward-looking statements
in this press release speak only as of the date of this document,
and we undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
Contacts:
Investors
Erika Trahan | ir@novavax.com
(240) 268-2022
Solebury Trout
Jennifer Porcelli | jporcelli@soleburytrout.com
(617) 974-8659
Media
Amy Speak | media@novavax.com
(617) 420-2461
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024